Trials / Completed
CompletedNCT04837235
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
Clinical Study of Safety, Tolerability, and Pharmacokinetics of Hemay005 Tablets in Single and Multiple Doses in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. There were 3 dose cohorts (75mg, 90mg, 105mg) with 12 healthy subjects in each cohorts (6 males and 6 females). This study includes an 11-day Screening Period, a 1-day single dose and 7-days multiple doses Treatment Period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hemay005 | oral |
Timeline
- Start date
- 2021-04-29
- Primary completion
- 2021-08-01
- Completion
- 2021-08-25
- First posted
- 2021-04-08
- Last updated
- 2024-03-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04837235. Inclusion in this directory is not an endorsement.